Patents by Inventor MARK LAUGHLIN
MARK LAUGHLIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8556397Abstract: An ink container usable with an image forming apparatus having a carriage to transport the ink container in a reciprocating motion across a substrate and an ink ejector to eject the ink onto the substrate is included. The ink container includes a chamber configured to supply ink to the ink ejector of the image forming apparatus. The ink container also includes a separation member disposed within the chamber configured to separate unwanted particles from the ink in response to the reciprocating motion of the carriage and gravity, and to direct the ink downstream to the ink ejector.Type: GrantFiled: December 15, 2009Date of Patent: October 15, 2013Assignee: Hewlett-Packard Development Company, L. P.Inventors: Jon Rittgers, Odhran Hendley, Mark Laughlin, Eduardo Macias, Michael Mulloy, Bryan Murphy
-
Patent number: 8114879Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.Type: GrantFiled: March 26, 2008Date of Patent: February 14, 2012Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Publication number: 20120013688Abstract: An ink container usable with an image forming apparatus having a carriage to transport the ink container in a reciprocating motion across a substrate and an ink ejector to eject the ink onto the substrate is included. The ink container includes a chamber configured to supply ink to the ink ejector of the image forming apparatus. The ink container also includes a separation member disposed within the chamber configured to separate unwanted particles from the ink in response to the reciprocating motion of the carriage and gravity, and to direct the ink downstream to the ink ejector.Type: ApplicationFiled: December 15, 2009Publication date: January 19, 2012Inventors: Jon Rittgers, Odhran Hendley, Mark Laughlin, Eduardo Macias, Michael Mulloy, Bryan Murphy
-
Publication number: 20100261739Abstract: A method of treating non-small cell lung cancer (NSCLC), and especially NSCLC that has metastasized to brain is disclosed.Type: ApplicationFiled: February 16, 2010Publication date: October 14, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventor: Mark Laughlin
-
Publication number: 20100137342Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions that are responsive to disruption of the vascular system, and in particular to its use in treating vascular macular degeneration.Type: ApplicationFiled: October 6, 2009Publication date: June 3, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: Mark Laughlin, Thomas L. Thorne
-
Publication number: 20100129470Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating brain cancer.Type: ApplicationFiled: October 8, 2009Publication date: May 27, 2010Applicant: Myriad Pharmaceuticals, IncorporatedInventor: MARK LAUGHLIN
-
Publication number: 20100093773Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating cancer.Type: ApplicationFiled: October 6, 2009Publication date: April 15, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventors: MARK LAUGHLIN, Mark B. Anderson, Adam Willardsen, Chris Pleiman
-
Publication number: 20100087457Abstract: In general, the invention relates to a pharmaceutical dose having (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride as the active ingredient that upon administration to a subject provides a Cmax of about 1 ng/mL to about 250 ng/mL. The dose may be used in methods of treating cancer through the administration of (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.Type: ApplicationFiled: October 7, 2009Publication date: April 8, 2010Applicant: Myriad Pharmaceuticals, IncInventor: MARK LAUGHLIN
-
Publication number: 20100087458Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating melanoma.Type: ApplicationFiled: October 7, 2009Publication date: April 8, 2010Applicant: Myriad Pharmaceuticals, Inc.Inventor: Mark Laughlin
-
Publication number: 20080188485Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.Type: ApplicationFiled: March 26, 2008Publication date: August 7, 2008Inventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Patent number: 7384944Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.Type: GrantFiled: September 23, 2003Date of Patent: June 10, 2008Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Publication number: 20080033045Abstract: The invention relates to the treatment of psychiatric disorders.Type: ApplicationFiled: July 9, 2007Publication date: February 7, 2008Applicant: Myriad Genetics, IncorporatedInventors: Mark Laughlin, Kenton Zavitz, Suzanne Hendrix
-
Patent number: 7247631Abstract: Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.Type: GrantFiled: May 6, 2003Date of Patent: July 24, 2007Assignee: Schering CorporationInventor: Mark A. Laughlin
-
Publication number: 20070015832Abstract: The invention relates to methods of treating or slowing the onset of overactive bladder or urinary incontinence, or a symptom thereof selected from urinary frequency, urinary urgency, nocturia, or enuresis comprising identifying and administering to a subject in need of treatment a therapeutically effective amount of a compound according to Formulae I-V, as defined herein.Type: ApplicationFiled: July 14, 2006Publication date: January 18, 2007Applicant: Myriad Genetics, IncorporatedInventor: Mark Laughlin
-
Publication number: 20070004635Abstract: A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.Type: ApplicationFiled: May 31, 2006Publication date: January 4, 2007Inventors: Janice Albrecht, Mark Laughlin, Bruce Malcolm
-
Publication number: 20040076609Abstract: Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.Type: ApplicationFiled: May 6, 2003Publication date: April 22, 2004Inventor: Mark A. Laughlin
-
Publication number: 20040067961Abstract: The use of CCR5 antagonists of the formula 1Type: ApplicationFiled: September 23, 2003Publication date: April 8, 2004Inventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Publication number: 20040058974Abstract: Methods of treating or preventing fungal infections in humans of 12 years and older in need of such treating or preventing which comprises orally administering an effective amount of posaconazole in divided doses two to four times a day to produce an arithmetic mean steady state average maximum plasma concentration of posaconazole of at least about 300 ng/mL to at least about 500.Type: ApplicationFiled: September 22, 2003Publication date: March 25, 2004Applicant: SCHERING CORPORATIONInventors: Rachel Courtney, Mark A. Laughlin
-
Patent number: 6689765Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v, host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV oType: GrantFiled: January 30, 2002Date of Patent: February 10, 2004Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Patent number: 6635646Abstract: Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.Type: GrantFiled: May 1, 2000Date of Patent: October 21, 2003Assignee: Schering CorporationInventor: Mark A. Laughlin